According to a report in BusinessWeek , pharmaceutical major, Eli Lilly & Co. (NYSE:LLY) (FRA:LLY), has won its case in the U.S. Court of Appeals relating to patent protection for its compound patent, for Alimta (premetrexed). The drug curtails the tendency of cancerous cells to use folic acid and grow regardless of treatment with drugs.
The ruling means that Alimta is protected in the U.S. up to January 2017.
The report cites Robert A. Armitage, senior vice president and general counsel of Eli Lilly & Co. (NYSE:LLY) (FRA:LLY), who says: "We are pleased...
Login required to continue reading.
Setup a free account to get access to this article (no credit card required).
View Full ArticleAlready a member? Log in here
